Chris Raymond
Stock Analyst at Raymond James
(2.98)
# 1,535
Out of 5,031 analysts
8
Total ratings
87.5%
Success rate
31.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Maintains: Strong Buy | $80 → $142 | $79.67 | +78.24% | 2 | Oct 6, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $31.92 | +40.98% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $14.50 | +141.38% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $92.52 | +13.49% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $4.63 | +396.76% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $16.39 | +83.04% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $15.95 | +370.22% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Oct 6, 2025
Maintains: Strong Buy
Price Target: $80 → $142
Current: $79.67
Upside: +78.24%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $31.92
Upside: +40.98%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $14.50
Upside: +141.38%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $92.52
Upside: +13.49%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $4.63
Upside: +396.76%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $16.39
Upside: +83.04%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $15.95
Upside: +370.22%